Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Friedrichshall – page 49

851 clinical trials in Bad Friedrichshall, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Friedrichshall at a glance
851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

851 trials in Bad Friedrichshall

Open in trial search

Study on the Effectiveness of Atezolizumab, Carboplatin, and Nab-Paclitaxel in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gout

Not recruiting

Study on Treating Acute Gout Attacks with Prednisolone and Colchicine for Primary Care Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitaetsmedizin Greifswald KöR

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of Avalotcagene Ontaparvovec for Patients Aged 12 and Older with Late-onset Ornithine Transcarbamylase Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sorafenib
  • Sponsor:Medical Center - University Of Freiburg

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Friedrichshall

What the registry says about research in the country

01 Cardiovascular Disease Research

Clinical trials focusing on atherosclerotic cardiovascular disease are evaluating innovative therapies to reduce major adverse cardiovascular events. These studies aim to improve outcomes for patients at high cardiovascular risk.

  • Coronary Heart Disease
  • Myocardial Infarction
  • Ischemic Stroke Prevention

Research emphasizes the development of new therapeutic approaches for arterial health management.

02 Heart Failure Studies

Groundbreaking research combines empagliflozin with novel compounds to address heart failure management. These trials specifically target patients with reduced left ventricular ejection fraction.

  • Combination Therapy Assessment
  • Cardiovascular Mortality Reduction
  • Hospital Admission Prevention

The studies aim to enhance current treatment protocols for heart failure patients.

03 Cardiac Rhythm Management

Important clinical research in atrial fibrillation and acute coronary syndrome is evaluating new anticoagulation strategies. These trials focus on preventing cardioembolic events and improving post-heart attack outcomes.

  • Stroke Prevention
  • Systemic Embolism Prevention
  • Post-Heart Attack Care

The research aims to establish more effective therapeutic options for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.